Zentalis Pharmaceuticals Inc [ZNTL] Investment Guide: What You Need to Know

Zentalis Pharmaceuticals Inc’s filing revealed that its Chief Executive Officer Blackwell Kimberly acquired Company’s shares for reported $51448.0 on Nov 13. In the deal valued at $10.29 per share,5,000 shares were bought. As a result of this transaction, Blackwell Kimberly now holds 254,800 shares worth roughly $3.08 million.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.

Then, Johnson David Michael bought 17,000 shares, generating $167,943 in total proceeds. Upon buying the shares at $9.88, the Director now owns 144,389 shares.

Before that, Brownstein Carrie sold 10,628 shares. Zentalis Pharmaceuticals Inc shares valued at $207,298 were divested by the Chief Medical Officer at a price of $19.50 per share. As a result of the transaction, Brownstein Carrie now holds 105,685 shares, worth roughly $1.28 million.

Wedbush downgraded its Zentalis Pharmaceuticals Inc [ZNTL] rating to a Neutral from an Outperform in a research note published on , November 08, 2023; the price target was decreased to $12 from $38.

Price Performance Review of ZNTL

On Tuesday, Zentalis Pharmaceuticals Inc [NASDAQ:ZNTL] saw its stock fall -8.05% to $12.10. Over the last five days, the stock has lost -11.16%. Zentalis Pharmaceuticals Inc shares have fallen nearly -20.13% since the year began. Nevertheless, the stocks have fallen -48.60% over the past one year. While a 52-week high of $31.46 was reached on 01/10/24, a 52-week low of $9.56 was recorded on 01/30/24. SMA at 50 days reached $13.31, while 200 days put it at $20.74. A total of 0.52 million shares were traded, compared to the trading of 0.49 million shares in the previous session.

Levels Of Support And Resistance For ZNTL Stock

The 24-hour chart illustrates a support level at 11.78, which if violated will result in even more drops to 11.45. On the upside, there is a resistance level at 12.73. A further resistance level may holdings at 13.35. The Relative Strength Index (RSI) on the 14-day chart is 37.69, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.81, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 99.58%. Stochastics %K at 8.14% indicates the stock is a buying.

How much short interest is there in Zentalis Pharmaceuticals Inc?

A steep rise in short interest was recorded in Zentalis Pharmaceuticals Inc stocks on Jan 11, 2024, growing by 1.48 million shares to a total of 13.07 million shares. Yahoo Finance data shows the prior-month short interest on Dec 14, 2023 was 11.59 million shares. There was a rise of 11.32%, which implies that there is a positive sentiment for the stock. In spite of short shares comprising just 25.14% of the overall stock float, the days-to-cover ratio (short ratio) rose to 12.75.

Leave a Reply

Your email address will not be published. Required fields are marked *

Most Popular